Key Takeaways Axsome reported Q3 loss of $0.94 per share, missing estimates but improving from last year's $1.34 loss.Revenues climbed 63% to $171M, led by 69% growth in Auvelity sales and steady gains for Sunosi.Symbravo recorded $2.1M in sales, while Axsome filed an sNDA for Auvelity in Alzheimer's agitation.Axsome Therapeutics (AXSM) incurred a loss of 94 cents per share in the third quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 82 cents. The company had incurred a loss of $1.34 p ...